Skip to main content

Table 10 Percentage change in ADC after NST

From: Factors affecting the value of diffusion-weighted imaging for identifying breast cancer patients with pathological complete response on neoadjuvant systemic therapy: a systematic review

First author After N cycles pCR versus non-pCR (mean ± SD%) ADC percentage change cutoff (%) ADC ratio pCR versus non pCRa AUC
ΔADC %
Santamaria [27] Post (~ 6 cycles)    1.788 ± 0.299 versus 1.487 ± 0.473 p = 0.009 0.73
Shin [26] Post 81.3 versus 12.6 p < 0.001 40.7b   0.96
Partridge [23] Post Overall: 64 ± 49 versus 50 ± 47; p = 0.013    0.61
   HR−/HER2−: 68 ± 32 versus 39 ± 39; p < 0.001    0.75
   HR+/HER2−: 82 ± 41 versus 54 ± 50; p = 0.01    0.71
   HR−/HER2+: 63 ± 79 versus 28 ± 46; p = 0.56    0.62
   HR+/HER2+: 43 ± 37 versus 61 ± 47; p = 0.64    0.55
  1. ADC apparent diffusion coefficient, AUC area under the curve, HER2 human epidermal growth factor receptor 2, HR hormone receptor, pCR pathological complete response, Δ representing change
  2. a\(\frac{{\text{ADC}}_{{\text{mean}}\, {\text{post}}}}{{\text{ADC}}_{{\text{mean}} \,{\text{pre}}}}\)
  3. bcorresponding to a sensitivity of 100% and specificity of 91%